Back to Exhibit Hall
Back to Main Conference

Biocartis is an innovative commercial stage molecular testing committed to revolutionize molecular testing with its unique proprietary IdyllaTM platform. We provide next generation testing solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and the healthcare industry, with a focus on oncology.

Visit Biocartis US

Idylla Workflow

Idylla automated molecular system workflow demo for outstanding ease of use in any lab setting.  Idylla Workflow

Products

Idylla Sars-COV-2 Test

The Idylla™ SARS-COV-2 Test is a fully automated rRT-PCR test intended for the qualitative detection of SARS-CoV-2 RNA in nasopharyngeal swab specimens from individuals suspected of COVID-19 by their healthcare provider.

Idylla for Oncollogy

THE IDYLLA™ – a revolutionary, fully automated system that makes molecular testing convenient and fast with only 2 minutes hands on time and TAT starting at 90 minutes.

Suitable for any lab setting, with rapid access to high-level Molecular testing, providing cancer patients with faster targeted therapy for the best possible patient outcome.

Idylla Oncology Menu

Gene content selected from relevant industry guidelines, key opinion leaders, and pharmaceutical research. Menu

0
Twitter
0
LinkedIn
0
Twitter

Contact

Jean-Jacques Jennings, M.Sc.Account Executive - New England / Upstate NY
Biocartis US, Inc.
30 Montgomery St, Suite 970 | Jersey City, NJ 07302 | USA
jjjennings@biocartis.com
Office: +1-844-4-IDYLLA (1-844-443-9552)
Mobile: +1-203-770-3284